Compositions for use in diagnostic screens for Mycoplasma haemofelis are provided. In one embodiment an immunogenic peptide selected from SEQ ID NO: 1 to SEQ ID NO: 60, or a fragment thereof, is immobilized on a solid support and is used to detect the presence of Mycoplasma haemofelis antibodies in a patient bodily fluid. In accordance with one embodiment a method for detecting a Mycoplasma haemofelis infection in a feline species, is provided.

The purpose of the present invention is to provide a specific antibody applicable to immunochromatographic detection of Mycoplasma pneumoniae infections, and a detection reagent using the same, among others. Provided are a Mycoplasma pneumoniae detection reagent and kit that include a specific antibody against the P30 protein of Mycoplasma pneumoniae, and an immunochromatographic test device.

The present invention provides methods and compositions for detecting Mycoplasma exposure in a subject.

Disclosed are methods and systems for analyte detection in a sample and more particularly, a biological sample. Methods and systems particularly relate to differentiating and/or identifying cell types in biological samples, such as blood samples, by adding antibodies specific to predetermined CD antigens. Other methods and systems relate to controlling the dynamic range of an assay for analyte detection.

The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.

A method of determining whether an individual is infected with a mycobacterial disease, the method comprising: (a) providing a system which comprises an antigen; (b) contacting the system with a sample obtained from the individual; and (c) detecting the presence or absence of binding of a biomarker in the sample with the antigen; wherein the antigen is an arabinose ester of a mycolic acid or an analogue thereof.

The present invention aims at providing a specific antibody that can simply and rapidly detect Mycoplasma pneumoniae which is a causative bacterium of mycoplasma pneumonia, with high sensitivity, and also an immunological detection method and a kit containing the same antibody. The present invention makes it possible to diagnose infection with Mycoplasma pneumoniae more rapidly and specifically than the conventional method, by producing an antibody recognizing a specific epitope of P30 protein of Mycoplasma pneumoniae and performing an immunological detection using the antibody. Also, the present invention enables easy and rapid detection of Mycoplasma pneumoniae and diagnosis of infection with the same at a hospital or the like without need of specialized instruments or skilled techniques.

This invention relates to methods and compositions for binding antibodies. The methods may be used to isolate antibodies, treat disorders related to excess antibodies, acutely block antibodies to stop an autoimmune or inflammatory response, and inhibit neutralizing antibodies. In embodiments, the invention relates to methods of inhibiting neutralizing antibodies against a heterologous agent when the heterologous agent is administered to a subject, comprising administering to the subject an effective amount of Mycoplasma protein M or a functional fragment or derivative thereof, thereby inhibiting neutralization of the heterologous agent. The invention further relates to modified Mycoplasma protein M or functional fragments thereof having increased thermostability relative to wild-type protein M and their use in the methods of the invention.

The present invention relates to diagnosing and classifying respiratory infections based on determined TK1 protein levels in body samples. In particular, a respiratory infection can be diagnosed and classified as Mycoplasma pneumonia caused by Mycoplasma pneumoniae based on the determined TK1 protein level.

The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.